By Angus Liu
In the next frontier of immuno-oncology competition focusing on treatment around surgery, Bristol Myers Squibb has snatched another U.S. license for Opdivo—this time in bladder cancer.
read more
By Robert King
Nursing home groups blasted a plan by CMS to require staff to get vaccinated, arguing such a mandate will make workforce shortages worse.
read more
By Angus Liu
Johnson & Johnson is switching captain to lead the world’s largest pharma company by 2020 revenue. Nine-year CEO Alex Gorsky will hand the helm to vice chairman of executive committee and leader of its COVID-19 response group, Joaquin Duato, early 2022.
read more
By Anastassia Gliadkovskaya
According to the latest AMGA medical group compensation and productivity survey, increases in compensation were modest, while there was a significant negative impact on productivity as a result of the COVID-19 pandemic.
read more
By Conor Hale
Drops in demand for COVID-19 screening have led test maker LumiraDx to dramatically cut back its plans for going public, slashing 40% off the value of a planned reverse merger.
read more
By Heather Landi
David Feinberg, who spent the past two years at Google leading the tech giant's health efforts, is moving over to lead Cerner after a three-month CEO search.
read more
By Beth Snyder Bulik
From home improvement shows to Louis Vuitton fashion, “Make it Yours” slogans have encouraged people to adopt their own style. Now, Moderna is using the tagline to encourage COVID-19 vaccinations.
read more
By Andrea Park
According to forms filed with the SEC this week, the FDA has temporarily paused its review of the multisource Nanox.ARC while it waits for Nanox to provide additional information about the X-ray bed.
read more
By Paige Minemyer
Major insurers are beginning to follow in the footsteps of big-name providers in mandating COVID-19 vaccines for their workforces.
read more
By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner
Regeneron's Roche-partnered monoclonal antibody, dubbed REGEN-COV in the U.S., has scored a nod from the U.K.'s drug regulator to treat and prevent COVID-19. AstraZeneca scored a win with promising late-stage trial data for its long-acting antibody cocktail. Plus more.
read more